In a recently published article in Arteriosclerosis, Thrombosis, and Vascular Biology, we assessed the impact of the promoter (T-786C) and exon 7 (G894T) polymorphism of the eNOS gene on endothelial function and endothelial response to physical exercise training in patients with coronary artery disease (CAD). 1 We were able to demonstrate, with a statistical power of 85%, that patients with CAD who were positive for the promoter (T-786C) or the exon 7 (G894T) polymorphism showed an impaired acetylcholine-mediated increase in blood flow average peak velocity compared with those with wild-type variants. 1 We point out that our study population consisted of carefully selected patients with CAD with a preserved left ventricular function who are suitable for a training program. The promoter polymorphism (T-786C) was shown to be associated with the occurrence of myocardial infarction and consequently reduced left ventricular function. 2 Because patients with an impairment of left ventricle function were excluded from study participation, this might explain why patients homozygous for the promoter polymorphism (T-786C) are underrepresented in our study population. 1 However, we did not exclude patients with myocardial infarction who had a global normal left ventricular function but local wall motion irregularities. Moreover, Nakayama et al clearly emphasized that the T-786C mutation is a feature of patients having an acute myocardial infraction caused by coronary vasospasm in the absence of a significant CAD. 2 In contrast, only 1 of 329 patients with stenosed coronary arteries was homozygous for the promoter polymorphism in their study, 2 which is in accordance with our data. 1 Nevertheless, the allele frequencies of the Asp 298 variant in our study are comparable to those of a recently published clinical trial involving 1850 white subjects. 3 We appreciate that Drs Maiolino and Rossi emphasized that there is much debate about the functional consequences of the exon 7 polymorphism (G894T). We are aware of Fairchild's study proving that acidic hydrolysis represents a mechanism for cleavage of the Glu 298 -Asp variant of eNOS. 4 However, the interpretation that this study, which also represents an artificial in vitro system, excludes all possibilities of a functional significance of the exon 7 polymorphism (G894T) in vivo seems to be a jumped-to conclusion. Numerous clinical trials are supporting the hypothesis of a physiological relevance of this polymorphism in vivo. One important study clearly revealed reduced eNOS activity in renal artery specimen from T allele carriers. 5 Moreover, the concept of a functional significance of this polymorphism is supported by an impaired platelet-derived NO release from healthy individuals harboring the exon 7 mutation (G894T). 6 These results are in accord with a recently published clinical trial involving 1850 patients with CAD. 3 It was shown that patients homozygous for the exon 7 polymorphism (G894T) had a higher risk for a major clinical cardiovascular event within 1 year after coronary stent implantation. 3 The knowledge about the physiological consequences on the endothelial level was further extended by Leeson et al. 7 They demonstrated an impairment of flow-mediated vasodilatation of the forearm in healthy young adults with the exon 7 polymorphism (G894T) in the presence of the environmental co-factor smoking. 7 Overall, our data do support the hypothesis that endothelial function in response to acetylcholine is impaired not only in promoter polymorphism (T-786C)-positive patients but also in patients with the exon 7 mutation (G894T). 1 Moreover, 4 weeks of physical exercise training resulted in a blunted endotheliumdependent increase in average peak velocity only in promoter polymorphism (T-786C)-positive patients but not in exon 7 (G894T) and wild-type allele carriers. 1 As it was acknowledged by Rossi and Maiolino, this finding might partially explain why some patients with CAD respond better to an exercise training intervention than do others. 8
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